ライフサイエンスコーパス: topoisomerase

1 pological enzymes, such as type I or type II topoisomerases).

2 NA synthesis, even in the absence of type II topoisomerase.

3 isome components and both type I and type II topoisomerases.

4 es $(K,\Delta Lk)$ in DNA induced by type-II topoisomerases.

5 ficient to take over the function of type 1A topoisomerases.

6 torsional stress injected in the molecule by topoisomerases.

7 tify drug-resistance mutations in eukaryotic topoisomerases.

8 ription and hyperproliferation by activating topoisomerases.

9 However, processing of rNMPs by Topoisomerase 1 (Top1) in absence of RER induces mutatio

10 fied depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and

11 lidation of a quinoline-based novel class of topoisomerase 1 (Top1) inhibitors and establish that com

12 Eukaryotic topoisomerase 1 (TOP1) regulates DNA topology to ensure

13 Topoisomerase 1 (TOP1) relieves torsional stress in DNA

14 lently closed circle of double-stranded DNA, topoisomerase 1 (Topo1) is thought to be required for pr

15 We also identified topoisomerase 1 as a cardinal Aire partner that colocali

16 hypomorphic mice accumulate DPCs containing Topoisomerase 1 covalently linked to DNA.

17 sm to K-PPn of two yeast proteins, Top1 (DNA topoisomerase 1) and Nsr1 (nuclear signal recognition 1)

18 RNA polymerase II is increased, and that of topoisomerase 1, an R-loop preventing factor, is decreas

19 tically predicted immunodominant peptides of topoisomerase 1, fibrillarin, and centromere protein A a

20 d into DNA during replication are removed by Topoisomerase 1, which generates 3' terminal adducts tha

21 Here we show that topoisomerase 1-DNA covalent cleavage complex (TOP1cc) i

22 ieties for degradation, including stabilized topoisomerase-1 cleavage complexes (Top1ccs).

23 Moreover, the DNA topoisomerase-1 inhibitor camptothecin (CPT) down-regula

24 promote DNA breaks via its interaction with topoisomerase 2 (TOP2).

25 ether with the downregulation of its target, Topoisomerase 2 alpha (TOP2A), in glioma cell lines, res

26 osyl-DNA phosphodiesterase 2 (TDP2) reverses Topoisomerase 2 DNA-protein crosslinks (TOP2-DPCs) in a

27 phosphodiesterase activity removing stalled topoisomerase 2 from DNA, TDP2 has also been shown to in

28 vant as Hat1-/- cells are hyper-sensitive to topoisomerase 2 inhibition suggesting that Hat1 is requi

29 The enrichment of topoisomerase 2 is functionally relevant as Hat1-/- cell

30 Hat1-/- nascent chromatin is enriched for topoisomerase 2alpha and 2beta.

31 DNA double strand breaks (DSBs) mediated by topoisomerase 2B (TOP2B).

32 DNA double-strand breaks (DSBs) mediated by Topoisomerase 2beta-DNA cleavage complex (TOP2betacc) in

33 gion sharing high homology with DDR proteins Topoisomerase 3alpha (TOP3alpha) and NEIL3 (Nei-like DNA

34 Topoisomerase 3beta (Top3beta) is the only dual-activity

35 have revealed unexpected roles of type I DNA topoisomerases, a subclass of these enzymes, in regulati

36 show how tight coupling of the helicase and topoisomerase activities allows for induction of positiv

37 Despite this essential role, abortive topoisomerase activity generates aberrant protein-linked

38 In particular, we observe that type-II topoisomerase activity is significantly enhanced in DNA

39 benzimidazoles (3, 6, 7, 8) also inhibit RNA topoisomerase activity of E. coli DNA topoisomerase I.

40 f endogenous lesions may arise from aberrant topoisomerase activity or ribonucleotide incorporation i

41 only known topoisomerase that possesses RNA topoisomerase activity, binds mRNA translation machinery

42 TOP2B encodes a type II topoisomerase, an essential gene required to alleviate t

43 most of these drugs target DNA synthesis or topoisomerase and cause DNA damage.

44 levant for the treatment of cancer with both topoisomerase and checkpoint inhibitors.

45 Finally, we show that targeting R-loops with topoisomerase and PARP inhibitors might be an effective

46 nt-derived cell lines exhibit sensitivity to topoisomerase and PARP inhibitors, defective sister chro

47 It has been reported that the absence of Topoisomerase and RNase H activity in Escherichia coli o

48 lution between the nuclear and mitochondrial topoisomerases and potential cancer predisposition.

49 ntial link between the catalytic activity of topoisomerases and the fundamental question regarding th

50 he coordinated action of multiple nucleases, topoisomerases, and helicases.

51 s focused on the biological functions of DNA topoisomerases, and several findings have revealed unexp

52 DNA topoisomerases are essential enzymes that control the to

53 oisomerases, the many lives of these type IA topoisomerases are now being progressively revealed.

54 nance of cccDNA and reveal that cellular DNA topoisomerases are required for both de novo synthesis a

55 DNA topoisomerases are required to resolve DNA topological s

56 DNA breaks generated by topoisomerases are short-lived because of the religation

57 Reverse gyrases (RGs) are the only topoisomerases capable of generating positive supercoils

58 Type II topoisomerases catalyze essential DNA transactions and a

59 In this review, we focus on how DNA topoisomerases catalyze their impressive range of DNA-co

60 In particular, type-II topoisomerases change both $K$ and $\Delta Lk$ by a dupl

61 apping of prokaryotic and eukaryotic type II topoisomerases cleavage sites in a variety of organisms

62 ph1 helicase and the Sgs1-Top3-Rmi1 helicase-topoisomerase complex.

63 Top3beta, but not other topoisomerases, contains a distinctive RNA-binding domai

64 opyran-based inhibitors of bacterial type II topoisomerases (DNA gyrase and topoisomerase IV) display

65 lve DNA-protein crosslinks (DPCs), including Topoisomerase-DNA adducts, during DNA replication.

66 ve sweeps of mutations including the primary topoisomerase drug targets, whereas biofilm-adapted popu

67 ndrial topoisomerase I (TOP1MT) is a type IB topoisomerase encoded in the nucleus of vertebrate cells

68 In this strain both type I topoisomerases, encoded by topA and topB, were dispensab

69 poisomerase IB (TOP1MT) is a nuclear-encoded topoisomerase, exclusively localized to mitochondria, wh

70 lass of antibiotics, which targets bacterial topoisomerases, fails to kill bacteria that have grown t

71 f this method to explore the role of diverse topoisomerase family members.

72 us and cytoplasm, but which one is the major topoisomerase for mRNAs is unclear.

73 Our data suggest that Top3beta is the major topoisomerase for mRNAs, and requires both RNA binding a

74 s binding of two ssDNA segments to a type IA topoisomerase has not been observed previously.

75 The topoisomerase I (TOP1) inhibitor irinotecan triggers cel

76 The 7-azaindenoisoquinolines are cytotoxic topoisomerase I (Top1) inhibitors.

77 Topoisomerase I (Top1) resolves supercoils by nicking on

78 e-strand breaks (DSBs) in cells depleted for Topoisomerase I (Top1), an enzyme that relaxes DNA super

79 transcription-associated damage in yeast is Topoisomerase I (Top1), an enzyme that removes torsional

80 by RNase H2-dependent excision repair or by topoisomerase I (Top1)-catalyzed cleavage.

81 Mitochondrial topoisomerase I (TOP1MT) is a type IB topoisomerase enco

82 that mutations in the gene encoding for DNA topoisomerase I (topA) give rise to mutator phenotypes w

83 nteraction between the C-terminal domains of topoisomerase I (TopoI-CTDs) and the beta' subunit of RN

84 In addition, the described ligand displayed topoisomerase I activity inhibition and self-fluorescenc

85 of RNAP convoy formation and is abrogated by topoisomerase I activity.

86 ing this assay, we found that all the tested topoisomerase I and II (TOP1 and TOP2, respectively) poi

87 Inhibition of topoisomerase I and II by camptothecin and etoposide tre

88 ations together, our study demonstrates that topoisomerase I and II may catalyze distinct steps of HB

89 e of the protein-protein interaction between topoisomerase I and RNA polymerase during stress respons

90 PB1 alleles using DNA obtained from 318 anti-topoisomerase I antibody-positive patients and 561 healt

91 NA binding domains to form diverse bacterial topoisomerase I enzymes that are highly efficient in the

92 in M. smegmatis competed with the endogenous topoisomerase I for protein-protein interactions with RN

93 is work, we have studied the requirement for topoisomerase I in B. subtilis.

94 n the essentiality of the topA gene encoding topoisomerase I in the model bacterium Bacillus subtilis

95 s a synergistic effect of MYC inhibition and topoisomerase I inhibition on anticancer activity.

96 yl side chains display excellent E. coli DNA topoisomerase I inhibition properties with IC50 values <

97 n synthesized and their Escherichia coli DNA topoisomerase I inhibition, binding to B-DNA duplex, and

98 nt anticancer activity do not exhibit strong topoisomerase I inhibition, suggesting a separate mechan

99 h clinically-relevant nanomolar doses of the Topoisomerase I inhibitor camptothecin, loss of WRN exon

100 , cleavable peptide-based linker, and potent topoisomerase I inhibitor payload.

101 HER2, a novel enzyme-cleavable linker, and a topoisomerase I inhibitor payload.

102 ntibody, cleavable peptide-based linker, and topoisomerase I inhibitor payload.

103 R-Cas9 screens in cells treated with the DNA topoisomerase I inhibitor topotecan.

104 latform, the effect of an apoptotic inducer, topoisomerase I inhibitor, 7-ethyl-10-hydrocamptothecin

105 s synthesized by conjugating camptothecin, a topoisomerase I inhibitor, to our proprietary, 'clickabl

106 Indenoisoquinolines are human topoisomerase I inhibitors in clinical testing with impr

107 p synthesis of a series of clinically active topoisomerase I inhibitors such as NSC 314622, LMP-400,

108 Measurements with Gyrase and Topoisomerase I inhibitors suggest hindrance to escape s

109 Camptothecins are potent topoisomerase I inhibitors used to treat high-risk pedia

110 amage induced by chemotherapy drugs, such as topoisomerase I inhibitors, results in S and G2 phase ar

111 DNA topoisomerase I is required for the relaxation of negati

112 tudy suggests that dual targeting of MYC and topoisomerase I may serve as a novel strategy for antica

113 A comparison of bacterial topoisomerase I structures showed that a conserved trans

114 oligonucleotides to Mycobacterium smegmatis topoisomerase I with progressive C-terminal deletions sh

115 se II, and BRD2 directly bound and activated topoisomerase I, a known restrainer of R-loops.

116 DNA ends, like camptothecin-induced trapped-topoisomerase I, can be mediated by TDP1, BRCA1, CtIP an

117 l linkers, selective inhibitors of bacterial topoisomerase I, have been evaluated using bacterial cyt

118 topoisomerase II is both structurally (e.g., topoisomerase I, Hsp90, and kinases) and functionally (e

119 analogues for their MYC-inhibitory activity, topoisomerase I-inhibitory activity, and anticancer acti

120 in vivo evaluation of the combination of DNA topoisomerase I-targeted drugs and mTOR kinase inhibitor

121 In this study, we found that DNA topoisomerase I-targeted drugs and mTOR kinase inhibitor

122 it RNA topoisomerase activity of E. coli DNA topoisomerase I.

123 in and amino acids of the active site of DNA topoisomerase I.

124 nitially hypersensitive to the inhibition of topoisomerase I/II and PARP, but acquire drug resistance

125 Here we encapsulated the topoisomerase-I inhibitor SN-38 in polymeric nanoparticl

126 of scleroderma induced by immunization with topoisomerase-I peptide-loaded dendritic cells, Mehta et

127 Mitochondrial topoisomerase IB (TOP1MT) facilitates mtDNA replication

128 Mitochondrial topoisomerase IB (TOP1MT) is a nuclear-encoded topoisome

129 y.DNA double-strand breaks (DSBs) induced by topoisomerase II (TOP2) are rejoined by TDP2-dependent n

130 Topoisomerase II (Top2) is an essential enzyme that deca

131 Topoisomerase II (Top2) is an essential enzyme that reso

132 DNA topoisomerase II (TOP2) is required for the unwinding an

133 We show that GCNA and topoisomerase II (TOP2) physically interact in both mice

134 n as a DUB inhibitor, PR-619 is a potent DNA topoisomerase II (TOP2) poison, inducing both DNA topois

135 Topoisomerase II (TOP2) poisons are effective cytotoxic

136 Topoisomerase II (TOP2) poisons as anticancer drugs work

137 that anthracyclines and mitoxantrone act as topoisomerase II (TOP2) poisons at low concentration but

138 how that the therapeutic cytotoxicity of DNA topoisomerase II (TOP2) poisons can be enhanced through

139 nd immature myeloid cells and transforms the topoisomerase II (TOP2) poisons etoposide and mitoxantro

140 s, in response to etoposide, an inhibitor of topoisomerase II (TOP2) re-ligation activity.

141 Topoisomerase II (TOP2) relieves topological stress in D

142 Topoisomerase II (TOP2) relieves torsional stress by for

143 sensitive measurements of the life essential topoisomerase II (Topo II) enzyme activity.

144 Topoisomerase II (Topo II) is essential for mitosis sinc

145 (AML) inhibit the activity of the mammalian topoisomerase II (topo II) isoforms, topo II alpha and t

146 olecular target of resveratrol is eukaryotic topoisomerase II (topo II), an enzyme essential for chro

147 We previously reported a first set of hybrid topoisomerase II (topoII) poisons whose chemical core me

148 roquinazoline derivatives that inhibit human topoisomerase II (topoII), a validated target of antican

149 , chromosomes present high levels of de novo Topoisomerase II (TopoII)-dependent re-entanglements, an

150 ce to anaphase, suggesting the importance of topoisomerase II activity for proper chromosome condensa

151 icated that XWL-1-48 significantly inhibited topoisomerase II activity in a concentration-dependent m

152 The inhibition of topoisomerase II activity using specific inhibitors reve

153 protein 4 (CBX4) transcriptionally activates Topoisomerase II alpha (TOP2alpha).

154 Anthracyclines interact with DNA and topoisomerase II as well as with cell membranes, and it

155 ring together with Treslin/TICRR and TopBP1 (Topoisomerase II binding protein 1 (TopBP1)-interacting

156 ETAA1 activator of ATR kinase (ETAA1) or DNA topoisomerase II binding protein 1 (TOPBP1).

157 ing resistance to poisons of human and yeast topoisomerase II derive from a rich mutational 'landscap

158 1 and TOP2, respectively) poisons as well as topoisomerase II DNA binding and ATPase inhibitors signi

159 pattern indicates the active requirement of topoisomerase II during these stages of the cell cycle.

160 KEY MESSAGE: The topoisomerase II expression varies as a function of cell

161 Maximal topoisomerase II expression was tightly coupled to S pha

162 cell cultures were used to study the role of topoisomerase II in various stages of the cell cycle.

163 for the adaptive response that bypasses the topoisomerase II inhibition----mediated G(2) arrest.

164 Mice were treated with vehicle, M3814 alone, topoisomerase II inhibitor alone, and M3814 in combinati

165 hibitor alone, and M3814 in combination with topoisomerase II inhibitor, and change in tumor volume o

166 showing that DJ34 is a DNA intercalator and topoisomerase II inhibitor.

167 e cellular ultrastructure that differed from topoisomerase II inhibitors including induction of spher

168 cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially selects for m

169 tivity of M3814 in combination with multiple topoisomerase II inhibitors, doxorubicin, etoposide, and

170 -damaging agents, including radiotherapy and topoisomerase II inhibitors.

171 Human DNA topoisomerase II is an important target in anticancer th

172 ual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomera

173 Contrary, topoisomerase II is not the major component of meiotic c

174 Even if topoisomerase II is required for individualization and c

175 Topoisomerase II is similarly required for linear chromo

176 he immuno-staining analysis also showed that topoisomerase II is the major component of mitotic chrom

177 ruplex ligand pyridostatin involves trapping topoisomerase II on DNA.

178 a cells confers collateral resistance to the topoisomerase II poison doxorubicin.

179 xerts its primary cytotoxic activity through topoisomerase II poisoning.

180 Topoisomerase II poisons are one of the most common clas

181 are selectively resistant to treatment with topoisomerase II poisons but not other DNA damaging agen

182 n the absence of cohesion, but inhibition of topoisomerase II prevents their resolution in anaphase.

183 We further show that topoisomerase II relaxation displays a strong preference

184 , small interfering RNA (siRNA) knockdown of topoisomerase II significantly reduced cccDNA amplificat

185 s the scientific background behind targeting topoisomerase II together with a number of other targets

186 Through immuno-localization of topoisomerase II was observed diffusely throughout the n

187 These breaks were reliant on topoisomerase II, and BRD2 directly bound and activated

188 ty to 12% of the tested compounds, including topoisomerase II, B-cell chronic lymphocytic leukemia/ly

189 te the clinical success of drugs that target topoisomerase II, the development of resistant cancer ce

190 els of random strand passage, for example by topoisomerase II, would result in entanglements, increas

191 ral products that bind to DNA and poison the topoisomerase II-DNA complex in cancer cells.

192 ation as biomarkers of responsiveness to DNA topoisomerase II-targeted therapy.

193 antibacterial ciprofloxacin can poison yeast topoisomerase II.

194 supercoiling is more efficiently removed by topoisomerase II.

195 se anthracyclines work in part by inhibiting topoisomerase-II (TOP2) on accessible DNA(3,4), we hypot

196 riant CENP-A and the DNA decatenizing enzyme topoisomerase-II (topo-II) as candidate modulators of ch

197 tumors displayed an enhanced response to the topoisomerase-II poison etoposide.

198 somerase II (TOP2) poison, inducing both DNA topoisomerase IIalpha (TOP2A) and DNA topoisomerase IIbe

199 We have identified topoisomerase IIalpha (TOP2A) as a DNA-binding factor re

200 Topoisomerase IIalpha (TOP2A) is a core component of mit

201 DNA topoisomerase IIalpha (Topo IIalpha) ensures genomic int

202 PICH function is apparent toward SUMOylated topoisomerase IIalpha (TopoIIalpha) after inhibition of

203 DNA breaks, histone eviction, and relocated topoisomerase IIalpha in living cells.

204 DNA topoisomerase IIalpha protein (TOP2alpha) 170 kDa (TOP2a

205 cate that miR-9-3p and miR-9-5p decrease DNA topoisomerase IIalpha protein 170 kDa expression levels

206 chromosomes during meiosis, localization of topoisomerase IIalpha to bivalents was not affected; how

207 dependent on tankyrase 1, condensin II, and topoisomerase IIalpha.

208 potential roles of host proteins, including topoisomerases IIalpha and IIbeta and PCNA, which were f

209 is the first to demonstrate the presence of topoisomerase IIbeta (TOP2B) as the only TOP2 isoform in

210 th DNA topoisomerase IIalpha (TOP2A) and DNA topoisomerase IIbeta (TOP2B) covalent DNA complexes with

211 pathway, STAT-5 increases expression of the topoisomerase IIbeta-binding protein 1 (TopBP1), a scaff

212 ATR activation requires the ATR activator, topoisomerase IIbeta-binding protein 1 (TopBP1).

213 ng tricks, with a particular emphasis on DNA topoisomerase III (TOP3).

214 the nucleotide turnover elements of type II topoisomerases impact drug specificity.

215 e 3beta (Top3beta) is the only dual-activity topoisomerase in animals that can change topology for bo

216 e ribosome, penicillin-binding proteins, and topoisomerases in a pharmacologically relevant phenotypi

217 increased, demonstrating the involvement of topoisomerases in DSB generation at the pausing sites.

218 thways of topology simplification by type-II topoisomerases in terms of stationary probability distri

219 Human cells contain five topoisomerases in the nucleus and cytoplasm, but which o

220 In this study, we investigated topoisomerase-induced DNA breaks and chromatin structura

221 mic distribution and mechanisms underpinning topoisomerase-induced DNA breaks, we map Top2 DNA cleava

222 res of an antiprotozoal agent and the potent topoisomerase inhibitor Tas-103.

223 One of them is microcin B17, a bacterial topoisomerase inhibitor whose activity depends on the co

224 the toxicity of a parenterally administered topoisomerase inhibitor, it enhanced the activity of dox

225 Novel bacterial topoisomerase inhibitors (NBTIs) provide a new strategy

226 of triple-negative breast cancer cells with topoisomerase inhibitors activates DNA damage response p

227 mulin, a pleuromutilin, and new nonquinolone topoisomerase inhibitors are attractive possibilities th

228 of small-molecule inhibitors, we identified topoisomerase inhibitors as a class of drugs that enhanc

229 Overall, recent clinical trials using topoisomerase inhibitors coupled with our findings of RA

230 enetically engineered oncolytic reovirus and topoisomerase inhibitors may provide a potent therapeuti

231 ated by forward genetics in combination with topoisomerase inhibitors more efficiently infect and kil

232 Therefore, topoisomerase inhibitors regulate SAMHD1 and HIV permiss

233 tization of cancer cells to the FDA-approved topoisomerase inhibitors topotecan and irinotecan.

234 This defines novel bacterial topoisomerase inhibitors with promising antibacterial ac

235 type II inhibitors known as "novel bacterial topoisomerase inhibitors", NBTIs.

236 lung cancer cells are largely insensitive to topoisomerase inhibitors, and depletion of PKCdelta can

237 -Ras-independent cells are more sensitive to topoisomerase inhibitors, and depletion of PKCdelta in t

238 such as fluoroquinolones and novel bacterial topoisomerase inhibitors, can trap DNA cleavage complexe

239 ic semiconductors from deoxyribonucleic acid topoisomerase inhibitors, featuring conjugated backbone

240 Bacterial type IIA topoisomerase inhibitors, such as fluoroquinolones and n

241 paves the way for future studies of various topoisomerase inhibitors.

242 ed RAMS11 expression increases resistance to topoisomerase inhibitors.

243 Type IA topoisomerases interact with G-strand and T-strand ssDNA

244 , the release of torsional strain by type II topoisomerases is critical for converging replisomes to

245 discrimination by prokaryotic and eukaryotic topoisomerases is vital to therapeutic utility, but is p

246 hen gyrase, the sole T. thermophilus type II topoisomerase, is inhibited, TtAgo allows the bacterium

247 get proteins-2 in DNA gyrase (GyrA) and 1 in topoisomerase IV (ParC), which occur in a stepwise manne

248 Topoisomerase IV also was able to distinguish DNA geomet

249 by 34, that inhibit bacterial DNA gyrase and topoisomerase IV and display potent activity against cip

250 Our results demonstrate that topoisomerase IV at increased expression is necessary an

251 ncodes a protein that does not interact with topoisomerase IV exhibit severe nucleoid decompaction le

252 ed with negatively supercoiled) DNA, whereas topoisomerase IV generated similar levels with both subs

253 Research into DNA gyrase and topoisomerase IV inhibitors has become a particular focu

254 ant to fluoroquinolones and other DNA gyrase/topoisomerase IV inhibitors used clinically.

255 ibacterial class of bacterial DNA gyrase and topoisomerase IV inhibitors.

256 in MukB and the cellular decatenating enzyme topoisomerase IV interact.

257 We show here that the MukB-topoisomerase IV interaction stabilizes MukB on DNA, inc

258 estigating the well-validated DNA gyrase and topoisomerase IV targets while preventing cross-resistan

259 us anthracis and Escherichia coli gyrase and topoisomerase IV to relax and cleave positively supercoi

260 s indicate that gyrase is better suited than topoisomerase IV to safely remove positive supercoils th

261 s aureus and Escherichia coli DNA gyrase and topoisomerase IV was identified.

262 erial type II topoisomerases (DNA gyrase and topoisomerase IV) display potent activity against Gram-p

263 ulates intramolecular reactions catalyzed by topoisomerase IV, supercoiled DNA relaxation, and DNA kn

264 the classical quinolone binding site in the topoisomerase IV-DNA cleavage complex but does not form

265 egion encompassing the parEC operon encoding topoisomerase IV.

266 dual inhibition of bacterial DNA gyrase and topoisomerase IV.

267 ll, Canela et al. (2017) reveal that type II topoisomerase-mediated release of torsional strain at ch

268 creasing the fitness benefit provided by DNA topoisomerase mutations under ciprofloxacin treatment.

269 such as helicases, DNA and RNA polymerases, topoisomerases, nucleosome remodelers, and motors involv

270 Inhibiting topoisomerases or depleting histone chaperones increased

271 Our findings support a model in which topoisomerases participate in Pol II promoter-proximal p

272 nding and cleavage region of human and yeast topoisomerases (particularly hTOP2beta) is additionally

273 Topoisomerases play crucial roles in DNA replication, tr

274 DNA topoisomerases play essential roles in chromosome organi

275 ential mechanism of developing resistance to topoisomerase poisons by ensuring rapid TOP2cc reversal.

276 By exploiting the ability of several topoisomerase poisons to stabilize this intermediate we

277 is, and at telomeres as well as from aborted topoisomerase reactions, collapsed replication forks, an

278 n during viral DNA replication by regulating topoisomerase recruitment to the replication origin.IMPO

279 Type II topoisomerases regulate DNA topology by making a double-

280 sing of a 50-nt non-coding gap in a phage T4 topoisomerase subunit gene (gp60) requires several recod

281 Inhibition of type II topoisomerases suppresses the action of other drugs that

282 DP1 inhibitors is proposed to synergize with topoisomerase targeting drugs to enhance selectivity aga

283 DNA gyrase is a bacterial DNA topoisomerase that catalyzes ATP-dependent negative DNA

284 To date, Top3beta is the only known topoisomerase that possesses RNA topoisomerase activity,

285 Once thought to be the most unremarkable of topoisomerases, the many lives of these type IA topoisom

286 ed through transient DNA fracture by type II topoisomerases to permit chromosome segregation during c

287 ausing sites indicated active recruitment of topoisomerases to these sites.

288 The DNA topoisomerases Top1 and Top2 and the HMGB family protein

289 A-phosphodiesterase I (TDP1) repairs type IB topoisomerase (TOP1) cleavage complexes generated by TOP

290 In contrast to the other five human topoisomerases, TOP1MT possesses two high frequency sing

291 nscription factors Tcf4 and Tbr1 and the RNA topoisomerase Top3b shared a neuronal phenotype marked b

292 Given type-II DNA topoisomerase (Topo II)-catalyzed topology fluctuations,

293 Type II topoisomerase (TopoII) enzymes play an important role in

294 In the absence of the topoisomerase topoIV, the site-specific recombination co

295 ne molecule is dispensable for the repair of topoisomerase type II (Top II) DNA adducts and associate

296 the description of a new class of bacterial topoisomerase type II inhibitors known as "novel bacteri

297 Most bacteria possess multiple topoisomerases which have specialized functions in the c

298 This duty is performed by DNA topoisomerases, which therefore are, unsurprisingly, ubi

299 port here the crystal structure of a type IA topoisomerase with ssDNA segments bound in opposite pola

300 The association of the topoisomerases with nascent DNA was dependent on express